RanitidineCAS# 66357-35-5 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 66357-35-5 | SDF | Download SDF |
PubChem ID | 3001055 | Appearance | Powder |
Formula | C13H22N4O3S | M.Wt | 314.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine | ||
SMILES | CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C | ||
Standard InChIKey | VMXUWOKSQNHOCA-UKTHLTGXSA-N | ||
Standard InChI | InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Ranitidine Dilution Calculator
Ranitidine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1807 mL | 15.9033 mL | 31.8066 mL | 63.6132 mL | 79.5165 mL |
5 mM | 0.6361 mL | 3.1807 mL | 6.3613 mL | 12.7226 mL | 15.9033 mL |
10 mM | 0.3181 mL | 1.5903 mL | 3.1807 mL | 6.3613 mL | 7.9517 mL |
50 mM | 0.0636 mL | 0.3181 mL | 0.6361 mL | 1.2723 mL | 1.5903 mL |
100 mM | 0.0318 mL | 0.159 mL | 0.3181 mL | 0.6361 mL | 0.7952 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 5'-Deoxy-5-fluorocytidine
Catalog No.:BCC8746
CAS No.:66335-38-4
- Dihydroguaiaretic acid
Catalog No.:BCN4212
CAS No.:66322-34-7
- ML 171
Catalog No.:BCC6252
CAS No.:6631-94-3
- 3H-1,2-Benzodithiol-3-one-1,1-dioxide
Catalog No.:BCC8633
CAS No.:66304-01-6
- Pregomisin
Catalog No.:BCN7000
CAS No.:66280-26-0
- Gomisin J
Catalog No.:BCN2270
CAS No.:66280-25-9
- 4-Amino-2-methylquinoline
Catalog No.:BCC8677
CAS No.:6628-04-2
- 6'-O-Acetylpaniculoside II
Catalog No.:BCC8316
CAS No.:
- Stemonidine
Catalog No.:BCC8253
CAS No.:66267-46-7
- N-dotriacontanol
Catalog No.:BCC8218
CAS No.:6624-79-9
- N-Benzylanthranilic acid
Catalog No.:BCC9093
CAS No.:6622-55-5
- Cyromazine
Catalog No.:BCC5328
CAS No.:66215-27-8
- Ranitidine Hydrochloride
Catalog No.:BCC4533
CAS No.:66357-59-3
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
- Methylsyringol
Catalog No.:BCN3535
CAS No.:6638-05-7
- (+)-Apogossypol
Catalog No.:BCC5585
CAS No.:66389-74-0
- Chloranthalactone A
Catalog No.:BCN8022
CAS No.:66395-02-6
- Chloranthalactone B
Catalog No.:BCN8020
CAS No.:66395-03-7
- 5alpha-Hydroxychloranthalactone A
Catalog No.:BCN7469
CAS No.:66395-04-8
- Pamoic acid disodium salt
Catalog No.:BCC7909
CAS No.:6640-22-8
- 13-Hydroxyoxyberberine
Catalog No.:BCN3355
CAS No.:66408-27-3
- 6-Amino-1,3-dimethyluracil
Catalog No.:BCC8755
CAS No.:6642-31-5
- 2-(2,4-Diaminophenoxy)ethanol dihydrochloride
Catalog No.:BCN8497
CAS No.:66422-95-5
- Kaempferol 3-O-(6''-O-acetyl)glucoside-7-O-rhamnoside
Catalog No.:BCN1385
CAS No.:66465-24-5
Ranitidine-induced Thrombocytopenia in a Neonate - A Case Report and Review of Literature.[Pubmed:30837818]
J Pediatr Pharmacol Ther. 2019 Jan-Feb;24(1):66-71.
Thrombocytopenia (platelet count <150 x 10(9)/L) regularly occurs in newborns but is especially observed in critically ill neonates. We describe the case of a small for gestational age (SGA) neonate, who showed an unexpected, severe thrombocytopenia (8 x 10(9)/L) at day 5 of life. The thrombocytopenia recovered completely after cessation of Ranitidine (0.5 mg/kg/6 hr), which was started in a context of feeding difficulties. Other causes of neonatal thrombocytopenia were ruled out. Besides a brief report on a cimetidine-induced thrombocytopenia over 25 years ago, no other neonatal or pediatric cases of H2 antagonist-induced thrombocytopenia have been reported to date, although being widely used in routine care. Moreover, several adult cases have been published. In general, neonatal thrombocytopenia, although one of the most frequent hematological conditions in newborns, is only rarely attributed to an adverse drug reaction. Clinicians should be aware of the risks for adverse reactions, especially in routinely used drugs and in critically ill patients.
Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine Solutions.[Pubmed:30718932]
Hosp Pharm. 2019 Feb;54(1):32-36.
Objectives: The physical compatibility and chemical stability of Ranitidine hydrochloride injectable solutions and oral syrup were studied to define beyond-use dates (BUDs). Methods: Ranitidine hydrochloride injectable solutions of 25 mg/mL packaged in glass vials and 5 mg/mL in polypropylene (PP) syringes were prepared in triplicate. Samples were refrigerated and protected from light (PFL) or stored at 25 degrees C and either exposed to light (ETL) or PFL. Ranitidine hydrochloride oral syrup 15 mg/mL in unit-dose amber PP syringes were prepared in triplicate and then kept at 25 degrees C. Samples were collected at days 0, 7, 14, 28, 56, and 91. Additional samples were collected at 6 months and at 6, 9, and 12 months for the 25 mg/mL solution and oral syrup, respectively. Physical parameters of pH, clarity, and color were obtained at each collection time. A validated stability-indicating high-performance liquid chromatography (HPLC) method was used to determine the chemical stability. Results: Formulations had no significant change in pH or clarity. Although some samples yellowed, this was not associated with a decrease in concentration. The 25 mg/mL solution remained above 98.6% for 6 months, whereas the 5 mg/mL solution remained above 93.5% for 91 days under all storage conditions. At 25 degrees C, the oral syrup retained greater than 98.8% for 12 months. Conclusions: The Ranitidine hydrochloride injectable solutions were stable for 6 months and 91 days under the 3 storage conditions, respectively, for the 25 mg/mL solution in glass vials and 5 mg/mL solution in PP syringes. The 15 mg/mL oral syrup in unit-dose amber PP syringes was stable for 12 months at 25 degrees C and PFL.